Products & ReviewClinical Diagnostics

SARS-CoV-2 Ag Pool Test

The LumiraDx SARS-CoV-2 Ag Pool Test is a rapid microfluidic immunofluorescence assay for the qualitative detection of the nucleocapsid protein antigen in nasal or nasopharyngeal swab specimens pooled from up to 5 individuals suspected of COVID-19 or up to 5 asymptomatic individuals. Used with the LumiraDx Platform the test offers a rapid, scalable and cost-effective screening solution for infectious individuals.

Request Pricing
LumiraDx

Receive your quote directly from the manufacturer.

Ease of Use
After Sales Service
Value for Money
Write your own review

Test benefits

  • Quickly and easily scale up testing: Low-cost diagnostic screening solutions
  • Maximize resources: Pooled testing can improve access to testing by significantly reducing resources (tests, operators, instruments) required on a per patient basis
  • Save Time: Pooled testing can result in a 40-60% reduction in testing, allowing for significant savings in both time and cost
  • High sensitivity of up to Ct 33 enables the accurate detection of the majority of infectious patients
  • Easy to implement in point of care settings
    • Room Temperature test strip storage
    • Time to result in 12 minutes
    • Compact and portable instrument with connectivity options
  • Facilitate reopening of work sites, sports, cultural venues and events and travel
    • Regular testing of defined populations e.g. healthcare staff, healthcare facility residents, employees, students
    • One time testing of groups for pre entry or reopening of sites

Product Overview

Links